WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to enable in vivo gene delivery, today announced that Roche (SIX: RO, ...

From vector design to GMP manufacturing, PackGene offers full-spectrum services to support drug discovery and development. Its proprietary π-alpha 293 AAV production platform delivers industry-leading ...

An R75W mutation in the gap junction β2 (GJB2) gene causes severe fragmentation of gap junction plaques, connecting adjacent cells and leading to syndromic hearing loss. In a new experimental study, ...

Researchers have developed an engineered adeno-associated virus (AAV) vector that yields high transduction of brain vascular pericytes and smooth muscle cells. The study describing the ...

Ainnocence is a biotech leader providing AI-powered drug discovery and therapeutic solutions across multiple industries, including biopharma, chemical, synthetic biology, and renewable energy. Its ...

Gene delivery vehicles have helped realize the concept of treating human diseases by introducing normal alleles of genes into appropriate target cells. These gene delivery vehicles include recombinant ...

Four oral presentations and seven poster presentations will share insights into AskBio's adeno-associated virus research, development and pre-clinical product progress Breadth of research reinforces ...

The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

The MarketWatch News Department was not involved in the creation of this content. -- Partnership reinforces PackGene's leadership in AAV solutions and rapid vector serotype screening -- Customizable ...